SMi is delighted to announce that John Maddox, Managing Director of Infusion Pharma Consulting LLC, has joined the speaker line-up for the 4th annual Orphan Drugs and Rare Diseases Conference.

In his unique presentation entitled "The Importance of Building Commercial Considerations into Orphan Drug Development from the Start", Mr. Maddox will discuss why it's vital to build these commercial considerations. He will also address the challenge of multi-indication products and will answer the question of how to support early market development efforts.   

SMi Group is delighted to present their 4th annual Orphan Drugs and Rare Diseases Conference, taking place in London, UK, on 19th - 20th October 2015. Through a series of interactive presentations and panel discussions, event attendees will be able to learn how pharmaceutical, biotech, patient organisations and academia are structuring to participate and leverage the growing orphan market.

Key topics include:

  • The development of ultra-orphan drugs to prevent, diagnose and treat rare diseases
  • Strategies for overcoming the challenges for reimbursement of orphan and ultra-orphan drugs
  • How to create workable partnerships for future development of drugs

For further information go to: www.orphandrugs-event.com/mednewstoday

Confirmed organisations include: GW Pharmaceuticals, PSR Orphan Experts, PSR Group B.V., Shire Pharmaceuticals Limited, Cello Health Insight - London, Infusion Pharma Consulting LLC, Otsuka Europe Development and Commercialisation

Event Speakers for 2015 include:

  • Dr Alastair Kent OBE, Director, Genetic Alliance UK, Chair, Rare Disease UK (RDUK)
  • Dr Niclas Sireau, Chairman & CEO, AKU Society
  • Dr Tim Miller, President & CEO, Abeona Therapeutics
  • Dr Anne Marquet, Principal Clinical Scientist, Rare Diseases, Roche Pharma Research and Early Development
  • Christine Lavary, Chief Executive, MPS Society UK
  • Dr Carlos R. Camozzi, Chief Medical Officer, Orphazyme
  • Michael Skynner, Head of Rare Disease External Alliances, Pfizer
  • David Boothe, Global Commercial Leader - GSK Rare Diseases, GSK
  • Dr Didier Caizergues, Head of regulatory Affairs Department, International Regulatory Affairs department, GENETHON
  • Stephane Demotz, Founder, DORPHAN S.A.
  • Tim Miller, President & CEO, Abeona Therapeutics

The event programme also includes two interactive half-day post-conference workshops:

A: Market access to orphan drugs: Controversies, trends and solutions
Workshop leader: Colette Hamilton, Managing Director, ATP Market Access

B: The rare disease patient perspective-from regulatory to clinical execution
Workshop leaders: Christa van Kan, Team Lead Clinical Execution, PSR Orphan Experts, Steve Phinder, PhD Director, Envestia Ltd, and Nicolas Sireau, PhD, Chairman and CEO, AKU Society

Sponsorship opportunities available. For more information please contact Alia Malick at +44 (0) 7827 6168 or email: amalick@smi-online.co.uk